Lund on July 31, 2018
Enzymatica signs agreement about the ColdZyme with ABEX Pharmaceuticals for south Africa</b>
Enzymatica has entered into a distribution agreement with ABEX Pharmaceuticals for the marketing and sales of förkylningssprayen ColdZyme
® in the south african market. The product will go on sale at the end of 2018.
ABEX sells to all major pharmacy chains, but also to retail stores in south Africa. The company plans to launch ColdZyme at the end of 2018, but with a focus on the south african winter season that extends from march to July. The company will implement a comprehensive marketing campaign with advertising in traditional media and in-store advertising as the commercials and marketing in social media.
The south african förkylningsmarknaden is expected to amount to approximately 2.1 billion Rand, the equivalent of about 1.4 billion SEK. Most förkylningspreparaten is a symptom alleviating and there are only a couple of pieces förkylningssprayer with a focus on cold viruses. It makes ABEX see great opportunities to position the ColdZyme as a very interesting treatment option in the segment.
We are very proud of our partnership with Enzymatica and be responsible for introducing the ColdZyme on the market. When there are no good treatment options available within the förkylningssegmentet, there is great potential for ColdZyme, which can be used both preventively and in order to shorten a cold, » says Ed Hallam, responsible for ABEX konsumentdivision.
We are very excited about this agreement with ABEX, which is a well established and reputable pharmaceutical company with a strong distribution system on the south african market, » says Fredrik Lindberg, CEO of Enzymatica.
ABEX Pharmaceuticals is a privately held pharmaceutical company that was founded in 2006 and has its head office in Port Elizabeth and with the sales and technology offices in Pretoria. The company also has representative offices in China, Hong Kong, Australia and the united kingdom. ABEX develops, manufactures and sells both pharmaceuticals and over-the-counter products (OTC — Over-the-Counter) and medical devices. The number of employees directly and indirectly, to about 30.
For more information, please contact:
Fredrik Lindberg, CEO Enzymatica AB
Tel: 0708-86 53 70 | E-mail: firstname.lastname@example.org
About Enzymatica AB
Enzymatica AB is a life science company that develops and sells medical products against infektionsrelaterade diseases. The products are based on a barriärteknologi, which includes marine enzymes. The company’s first product is the ColdZyme® mouth spray, which can prevent colds, and can shorten the you are not. The product has been launched in a dozen markets. The strategy is to continue to grow by strengthening its position in existing markets and expand into more geographic markets via the established partners. The company has headquarters in Lund, sweden and is listed on Nasdaq First North. For more information, please visit: www.enzymatica.se.
The Certified Adviser is Erik Penser Bank.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Enzymatica AB via Globenewswire